Mesoblast is in active discussions with US and other government authorities as well as potential pharmaceutical partners with respect to its plans for ramp-up of commercial manufacturing for remestemcel-L in COVID-19 ARDS.2
Ann: Appendix 4C - quarterly
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
77.5¢ |
Change
0.025(3.33%) |
Mkt cap ! $884.8M | |||
| Open | High | Low | Value | Volume |
| 76.0¢ | 79.5¢ | 76.0¢ | $5.745M | 7.394M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 35920 | 77.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 78.0¢ | 99172 | 5 |
View Market Depth
| Last trade - 16.10pm 18/04/2024 (20 minute delay) ? |
|
|||||
|
Last
77.0¢ |
Change
0.025 ( 2.79 %) |
||||
| Open | High | Low | Volume | ||
| 76.5¢ | 79.5¢ | 76.3¢ | 2269958 | ||
| Last updated 15.59pm 18/04/2024 ? | |||||
| MSB (ASX) Chart |